Therefore, pharmaceutical GLP-1 analogues that are resistant to inactivation by DPP-4 have been developed with an improved pharmacokinetic profile related to a longer half-life, of which exenatide (a synthetic version of exendin-4) was approved in 2005 for the treatment of T2DM [11]. Here, DPP4 is linked to type 2 diabetes mellitus.